2025 Q3 -tulosraportti
Vain PDF
51 päivää sitten
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 560
Myynti
Määrä
25 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 698 | NRD | DDB | ||
| 697 | NON | DDB | ||
| 121 | NON | SSWM | ||
| 3 | NON | NON | ||
| 1 | NON | NON |
Ylin
0,645VWAP
Alin
0,434VaihtoMäärä
0 1 995
VWAP
Ylin
0,645Alin
0,434VaihtoMäärä
0 1 995
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.10. | |
| 2025 Q2 -tulosraportti | 25.8. | |
| 2025 Q1 -tulosraportti | 28.4. | |
| 2024 Q4 -tulosraportti | 17.2. | |
| 2024 Q3 -tulosraportti | 22.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12.12.Has anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid economy. If one were to point to a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. Recently, they hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have myself taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf
·3 päivää sittenYou write a nice long analysis and arrive at one critical point concerning the company's IR function. It appears somewhat comical. The IR function is a staff function and it is difficult to imagine that it is critical for the business or decisive for whether the business succeeds or not. Do you have no critical remarks about the operation itself?·1 päivä sittenMaybe yes, but that certainly applies to you @blueoceanguy. The only thing that is certain is that I would never write an analysis where I only found criticism of the IR department.
·24.11.What I would like to know is: will they still be delisted, now that they have sold to Stenocare and have received 5 million shares. Because I can well imagine the thought that they will still be delisted and that the company retains the shares and at some point sells them, but that it only benefits the management and that it is then them who keep the money.
·19.11.The Shares are currently trading at a market value of 2,3 million, but they have just received Shares in SC for 11 million. The Price of the shares should be much higher!
·21.11.Hard to say, but it certainly looks significantly better now than a week ago.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
51 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12.12.Has anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid economy. If one were to point to a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. Recently, they hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have myself taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf·3 päivää sittenYou write a nice long analysis and arrive at one critical point concerning the company's IR function. It appears somewhat comical. The IR function is a staff function and it is difficult to imagine that it is critical for the business or decisive for whether the business succeeds or not. Do you have no critical remarks about the operation itself?·1 päivä sittenMaybe yes, but that certainly applies to you @blueoceanguy. The only thing that is certain is that I would never write an analysis where I only found criticism of the IR department.
- ·24.11.What I would like to know is: will they still be delisted, now that they have sold to Stenocare and have received 5 million shares. Because I can well imagine the thought that they will still be delisted and that the company retains the shares and at some point sells them, but that it only benefits the management and that it is then them who keep the money.
- ·19.11.The Shares are currently trading at a market value of 2,3 million, but they have just received Shares in SC for 11 million. The Price of the shares should be much higher!·21.11.Hard to say, but it certainly looks significantly better now than a week ago.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 560
Myynti
Määrä
25 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 698 | NRD | DDB | ||
| 697 | NON | DDB | ||
| 121 | NON | SSWM | ||
| 3 | NON | NON | ||
| 1 | NON | NON |
Ylin
0,645VWAP
Alin
0,434VaihtoMäärä
0 1 995
VWAP
Ylin
0,645Alin
0,434VaihtoMäärä
0 1 995
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.10. | |
| 2025 Q2 -tulosraportti | 25.8. | |
| 2025 Q1 -tulosraportti | 28.4. | |
| 2024 Q4 -tulosraportti | 17.2. | |
| 2024 Q3 -tulosraportti | 22.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
Vain PDF
51 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.10. | |
| 2025 Q2 -tulosraportti | 25.8. | |
| 2025 Q1 -tulosraportti | 28.4. | |
| 2024 Q4 -tulosraportti | 17.2. | |
| 2024 Q3 -tulosraportti | 22.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12.12.Has anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid economy. If one were to point to a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. Recently, they hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have myself taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf·3 päivää sittenYou write a nice long analysis and arrive at one critical point concerning the company's IR function. It appears somewhat comical. The IR function is a staff function and it is difficult to imagine that it is critical for the business or decisive for whether the business succeeds or not. Do you have no critical remarks about the operation itself?·1 päivä sittenMaybe yes, but that certainly applies to you @blueoceanguy. The only thing that is certain is that I would never write an analysis where I only found criticism of the IR department.
- ·24.11.What I would like to know is: will they still be delisted, now that they have sold to Stenocare and have received 5 million shares. Because I can well imagine the thought that they will still be delisted and that the company retains the shares and at some point sells them, but that it only benefits the management and that it is then them who keep the money.
- ·19.11.The Shares are currently trading at a market value of 2,3 million, but they have just received Shares in SC for 11 million. The Price of the shares should be much higher!·21.11.Hard to say, but it certainly looks significantly better now than a week ago.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 560
Myynti
Määrä
25 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 698 | NRD | DDB | ||
| 697 | NON | DDB | ||
| 121 | NON | SSWM | ||
| 3 | NON | NON | ||
| 1 | NON | NON |
Ylin
0,645VWAP
Alin
0,434VaihtoMäärä
0 1 995
VWAP
Ylin
0,645Alin
0,434VaihtoMäärä
0 1 995
Välittäjätilasto
Dataa ei löytynyt